drugset / Trial / NCT00599287
Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.
Timeline
- Start
- 2008-02
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Haloperidol | Other / unclassified | 1 mg | Oral |
| Subject | Haloperidol | Other / unclassified | 2.5 mg | Oral |
| Subject | Methylphenidate | Small molecule | 30 mg | Oral |
| Subject | Rivastigmine | Small molecule | 12 mg | Oral |